EP1073419A4 - Composition a liberation prolongee contenant un polymre amorphe - Google Patents

Composition a liberation prolongee contenant un polymre amorphe

Info

Publication number
EP1073419A4
EP1073419A4 EP99912785A EP99912785A EP1073419A4 EP 1073419 A4 EP1073419 A4 EP 1073419A4 EP 99912785 A EP99912785 A EP 99912785A EP 99912785 A EP99912785 A EP 99912785A EP 1073419 A4 EP1073419 A4 EP 1073419A4
Authority
EP
European Patent Office
Prior art keywords
sustained
composition including
release composition
amorphous polymer
including amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912785A
Other languages
German (de)
English (en)
Other versions
EP1073419A2 (fr
Inventor
Theodore W Randolph
Mark C Manning
Richard F Falk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Technology Corp
Original Assignee
University of Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Technology Corp filed Critical University of Technology Corp
Publication of EP1073419A2 publication Critical patent/EP1073419A2/fr
Publication of EP1073419A4 publication Critical patent/EP1073419A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99912785A 1998-03-18 1999-03-18 Composition a liberation prolongee contenant un polymre amorphe Withdrawn EP1073419A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7839098P 1998-03-18 1998-03-18
US78390P 1998-03-18
PCT/US1999/006198 WO1999047543A2 (fr) 1998-03-18 1999-03-18 Composition a liberation prolongee contenant un polymre amorphe

Publications (2)

Publication Number Publication Date
EP1073419A2 EP1073419A2 (fr) 2001-02-07
EP1073419A4 true EP1073419A4 (fr) 2009-03-25

Family

ID=22143753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912785A Withdrawn EP1073419A4 (fr) 1998-03-18 1999-03-18 Composition a liberation prolongee contenant un polymre amorphe

Country Status (5)

Country Link
EP (1) EP1073419A4 (fr)
JP (1) JP2002506876A (fr)
AU (1) AU3108299A (fr)
CA (1) CA2324254C (fr)
WO (1) WO1999047543A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815540B1 (fr) † 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
NZ530315A (en) * 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
EP1452177A1 (fr) * 2003-02-27 2004-09-01 Boehringer Ingelheim International GmbH Compositions pharmaceutiques contenant du laurylsulfate de sodium comme agent qui masque l'amertume
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
WO2008070118A1 (fr) 2006-12-05 2008-06-12 Landec Corporation Administration de médicaments
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
WO2009100222A1 (fr) 2008-02-08 2009-08-13 Qps Llc Compositions non polymères pour l'administration contrôlée de médicament
US20160175313A1 (en) * 2013-08-06 2016-06-23 Dongkook Pharmaceutical Co., Ltd., Entecavir microspheres and pharmaceutical composition for parenteral administration containing same
AU2015316252A1 (en) * 2014-09-10 2017-03-09 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs
WO2017153052A1 (fr) * 2016-03-07 2017-09-14 Double Bond Pharmaceuticals Ab Administration ciblée de médicaments hydrophiles dans les poumons

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029998A1 (fr) * 1995-03-28 1996-10-03 Fidia Advanced Biopolymers S.R.L. Nanospheres contenant un polysaccharidique biocompatible
WO1997038698A1 (fr) * 1996-04-18 1997-10-23 University Technology Corporation Procedes pour le traitement de troubles de l'oreille interne et moyenne

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
WO1994008599A1 (fr) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Appariement d'ions de medicaments pour ameliorer l'efficacite et l'administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029998A1 (fr) * 1995-03-28 1996-10-03 Fidia Advanced Biopolymers S.R.L. Nanospheres contenant un polysaccharidique biocompatible
WO1997038698A1 (fr) * 1996-04-18 1997-10-23 University Technology Corporation Procedes pour le traitement de troubles de l'oreille interne et moyenne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9947543A3 *

Also Published As

Publication number Publication date
CA2324254C (fr) 2005-01-04
WO1999047543A2 (fr) 1999-09-23
EP1073419A2 (fr) 2001-02-07
WO1999047543A3 (fr) 1999-11-04
CA2324254A1 (fr) 1999-09-23
JP2002506876A (ja) 2002-03-05
AU3108299A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
HUP0000660A3 (en) Epoxy-polysiloxane polymer composition
EG22389A (en) Novel polymers
IL124819A0 (en) Polymer compositions
GB9811813D0 (en) Polymeric compounds
ZA983899B (en) Polymer compositions
GB9802181D0 (en) Polymer compositions
EP1073419A4 (fr) Composition a liberation prolongee contenant un polymre amorphe
GB9806788D0 (en) Composition
GB9906149D0 (en) Polymer composition
GB9805693D0 (en) Polymeric composition
GB9800685D0 (en) Polymer composition
GB9815730D0 (en) Polymer composition
PL344137A1 (en) Novel composition
GB9726408D0 (en) Polymer composition
GB9804041D0 (en) Composition
GB9817607D0 (en) Polymer blends
GB9809208D0 (en) Polymer blends
HUP9901556A3 (en) Polymer compositions
GB9802380D0 (en) Polymer compositions
GB9806791D0 (en) Composition
GB9817728D0 (en) Polymer composition
ZA987395B (en) Polymer composition
GB9805141D0 (en) Polymer composition
GB9812035D0 (en) Polymer blends
GB9716375D0 (en) Polymer composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001002

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20090225

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090527